hit counter
Can-Fite BioPharma Ltd. (CANF) Stock News Sentiment & Price - Sentifly
CANF - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Can-Fite BioPharma Ltd. (CANF)

Israel
Biotechnology
NYSE
CANF Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CANF Latest news
Business Wire
Neutral
Can-Fite's Findings on Cannabis Compound's Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD's The Liver Meeting® 2021 Conference
2021-11-01 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Findings on Cannabis Compound's Inhibition of Liver Cancer Published in HEPATOLOGY and will be Presented at the AASLD's The Liver Meeting®

Business Wire
Neutral
Can-Fite's NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico
2021-10-28 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its patent titled "An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation" has been granted in Hong Kong and Mexico, and has received a notice of allowance in Japan. This patent addresses the use of the A3 Adenosine Recept

Business Wire
Neutral
Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
2021-10-26 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit

Benzinga
Positive
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
2021-10-21 09:25

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Alimentary Pharmacology & Therapeutics, a peer reviewed scientific journal focused on gastroenterology and hepatology, published an article titled “Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis" authored by Can-Fite's CEO Dr. Pnina Fishman.

Business Wire
Neutral
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
2021-10-21 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Alimentary Pharmacology & Therapeutics, a peer reviewed scientific journal focused on gastroenterology and hepatology, published an article titled “Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatt

Business Wire
Neutral
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
2021-10-05 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

Business Wire
Neutral
Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
2021-09-17 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences

Business Wire
Neutral
Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-09 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire
Neutral
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
2021-09-02 07:00

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study

Benzinga
Negative
Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY
2021-08-26 12:48

Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021.

Loading more news...